MGR001

DRUG2 trials

Sponsors

Mylan Pharma UK Ltd.

Conditions

AsthmaCOPD

Phase 1

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

CompletedNCT02215122

Mylan Pharma UK Ltd.Asthma, COPD

Start: 2013-10-31End: 2013-11-30Updated: 2022-03-07

An Open Study to Assess the Robustness of the CRC749 Inhaler

CompletedNCT02474017

Mylan Pharma UK Ltd.Asthma, COPD

Start: 2015-05-31End: 2015-06-30Updated: 2022-03-07

Related Papers

Usability and Robustness of the Wixela Inhub Dry Powder Inhaler

Journal of Aerosol Medicine and Pulmonary Drug Delivery2020-08-3112 citations